A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)

James I. Geller, John P. Perentesis, Xiaowei Liu, Charles G. Minard, Rachel A. Kudgus, Joel M. Reid, Elizabeth Fox, Susan M. Blaney, Brenda J. Weigel

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111)'. Together they form a unique fingerprint.

Medicine & Life Sciences